prognostic tools

A New Genetic Test To Help You Understand Your Risk For A Prostate Cancer Recurrence

Base on a recently published news release, a prospective study performed and funded by the commercial company GenomeDx Biosciences showed that their new Decipher Cancer Classifier test reclassifies the tumor aggressiveness in men who have had surgery as their primary prostate cancer treatment. According to the company, this newly validated test will improve clinical decision-making following a radical prostatectomy. In this validation study, their Decipher Post-Op test was able to reclassified the tumor aggressiveness in a large number of men based on the genomic risk assessment as compared to our current clinical and pathological risk assessment tools. The company claims [...]

By | September 12th, 2016|Genetic testing, genetics, prognostic tools, Uncategorized|0 Comments

Is Alkaline Phosphatase A Bio-Marker To Predict PSA Decline And Clinical Benefit From Abiraterone Acetate in Bone Metastatic Castration Resistant Prostate Cancer

Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t exist, so a lot of clinical decision-making is based upon the experience and gut feeling of our doctors. This type of decision-making is not adequate in today’s world of multiple treatment options, especially when many of the treatments can foster resistance to other available treatments. [...]

Some Factors That Might Be Predictors of the Duration of Abiraterone Acetate in Men with Castration-Resistant Prostate Cancer

Being able to make better decisions about drug sequencing and combinations has become one of the current hot topics in prostate cancer research. Given that we have a number of newer drugs to use this is an important clinical issue as we make important treatment decisions. Making these clinical decisions is tough.  The fact is that prostate cancer is a very heterogeneous disease and so  drug  responses are not consistent. Compounded by the fact that none of our treatments are effective for an extended time period knowing how to accurately predict drug response is vital. One  example of research dealing [...]

Better Predicting Advanced Prostate Cancer Outcomes with NaF-PET/CT Scans

Imaging of prostate cancer has been improving by leaps and bounds over the last few years. Current imaging techniques are not sensitive enough to give us an accurate picture of the cancer. This means that we lose predictive abilities and don’t always have adequate information to make the best treatment decisions. It also means, in some situations, that insurance will not always cover what is clearly the best treatment because we lack evidence of the actual disease state to qualify for the FDA label of certain treatments. In a move to develop better, more accurate scanning technology, a recent study [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー